These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 36621810)
21. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. León-Mateos L; Mosquera J; Antón Aparicio L Redox Biol; 2015 Dec; 6():421-425. PubMed ID: 26386874 [TBL] [Abstract][Full Text] [Related]
22. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Gupta R; Maitland ML Curr Hypertens Rep; 2011 Dec; 13(6):430-5. PubMed ID: 21931979 [TBL] [Abstract][Full Text] [Related]
23. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Plummer C; Michael A; Shaikh G; Stewart M; Buckley L; Miles T; Ograbek A; McCormack T Br J Cancer; 2019 Jul; 121(2):109-116. PubMed ID: 31182765 [TBL] [Abstract][Full Text] [Related]
30. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655 [TBL] [Abstract][Full Text] [Related]
32. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Steeghs N; Gelderblom H; Roodt JO; Christensen O; Rajagopalan P; Hovens M; Putter H; Rabelink TJ; de Koning E Clin Cancer Res; 2008 Jun; 14(11):3470-6. PubMed ID: 18519779 [TBL] [Abstract][Full Text] [Related]
33. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. Thompson LA; Saseen JJ; O'Bryant CL; Allen RR; Nair KV J Oncol Pharm Pract; 2015 Aug; 21(4):258-67. PubMed ID: 24727344 [TBL] [Abstract][Full Text] [Related]
34. Anti-VEGF Anticancer Drugs: Mind the Hypertension. Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049 [TBL] [Abstract][Full Text] [Related]
35. Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. Budolfsen C; Faber J; Grimm D; Krüger M; Bauer J; Wehland M; Infanger M; Magnusson NE Curr Vasc Pharmacol; 2019; 17(6):618-634. PubMed ID: 30706818 [TBL] [Abstract][Full Text] [Related]
36. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Roodhart JM; Langenberg MH; Witteveen E; Voest EE Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886 [TBL] [Abstract][Full Text] [Related]
37. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247 [TBL] [Abstract][Full Text] [Related]
38. [Cardiac Dysfunction and Arterial Hypertension as Manifestations of Cardiovasculotoxicity of iVEGF-Containing Chemotherapy. Clinical Case]. Kirichenko YY; Kulagina TY; Zhigulina OA; Ilgisonis IS; Belenkov YN Kardiologiia; 2024 May; 64(5):33-38. PubMed ID: 38841787 [TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165 [TBL] [Abstract][Full Text] [Related]